Enter drug's generic or brand name below. Results will appear here. Note: all drug related information obtained on this page is provided by RX List.
Using the RX LIST database:
(1) Enter the drug name in the search box below and hit ENTER
(2) The rx list web site will open here with the drug search completed. Next, scroll down the page to locate the link to the drug you are searching for and then click on the link.
PIFELTRO is a film-coated tablet containing doravirine for oral administration.
Doravirine is an HIV-1 non-nucleoside reverse transcriptase inhibitor (NNRTI).
Each tablet contains 100 mg of doravirine as the active ingredient. The tablets include the following inactive ingredients: colloidal silicon dioxide, croscarmellose sodium, hypromellose acetate succinate, lactose monohydrate, magnesium stearate, and microcrystalline cellulose. The tablets are film coated with a coating material containing the following inactive ingredients: hypromellose, lactose monohydrate, titanium dioxide, and triacetin. The coated tablets are polished with carnauba wax.
The chemical name for doravirine is 3-chloro-5-[[1-[(4,5-dihydro-4-methyl-5-oxo-1H-1,2,4-triazol-3- yl)methyl]-1,2-dihydro-2-oxo-4-(trifluoromethyl)-3-pyridinyl]oxy]benzonitrile.
It has a molecular formula of C17H11ClF3N5O3 and a molecular weight of 425.75. It has the following structural formula:
 |
Doravirine is practically insoluble in water.
PIFELTRO® is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 35 kg:
The recommended dosage regimen of PIFELTRO in adults and pediatric patients weighing at least 35 kg is one 100 mg tablet taken orally once daily with or without food [see CLINICAL PHARMACOLOGY].
If PIFELTRO is co-administered with rifabutin, increase PIFELTRO dosage to one tablet twice daily (approximately 12 hours apart) for the duration of rifabutin co-administration [see DRUG INTERACTIONS and CLINICAL PHARMACOLOGY].
PIFELTRO film-coated tablets are white, oval-shaped tablets, debossed with the corporate logo and 700 on one side and plain on the other side. Each tablet contains 100 mg doravirine.
Each PIFELTRO tablet contains 100 mg of doravirine, is white, oval-shaped and filmcoated, and is debossed with the corporate logo and 700 on one side and plain on the other side. Each bottle contains 30 tablets (NDC 0006-3069-01) with silica gel desiccant and is closed with a child-resistant closure.
Store PIFELTRO in the original bottle. Keep the bottle tightly closed to protect from moisture. Do not remove the desiccant.
Store PIFELTRO at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature].
Manufactured for: Merck Sharp & Dohme LLC, Rahway, NJ 07065, USA. Revised: Nov 2024
The following adverse reactions are discussed in other sections of the labeling:
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
The safety assessment of PIFELTRO used in combination with other antiretroviral agents is based on Week 96 data from two Phase 3, randomized, international, multicenter, double-blind, active-controlled trials (DRIVE-FORWARD (Protocol 018) and DRIVE-AHEAD (Protocol 021)).
In DRIVE-FORWARD, 766 adult participants received either PIFELTRO 100 mg (n=383) or darunavir 800 mg + ritonavir 100 mg (DRV+r) (n=383) once daily, each in combination with emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) or abacavir/lamivudine (ABC/3TC). By Week 96, 2% in the PIFELTRO group and 3% in the DRV+r group had adverse events leading to discontinuation of study medication.
In DRIVE-AHEAD, 728 adult participants received either DELSTRIGO [doravirine (DOR)/3TC/TDF] (n=364) or efavirenz (EFV)/FTC/TDF once daily (n=364). By Week 96, 3% in the DELSTRIGO group and 7% in the EFV/FTC/TDF group had adverse events leading to discontinuation of study medication.
Adverse reactions reported in greater than or equal to 5% of participants in any treatment group in DRIVE-FORWARD and DRIVE-AHEAD are presented in Table 1.
Table 1: Adverse Reactions (All Grades)* Reported in ≥5%† of Participants in Any Treatment Group in Adults with No Antiretroviral Treatment History in DRIVE-FORWARD and DRIVE-AHEAD (Week 96)
| DRIVE-FORWARD | DRIVE-AHEAD | |||
| PIFELTRO + 2 NRTIs‡ Once Daily N=383 |
DRV+r+2 NRTIs‡ Once Daily N=383 |
DELSTRIGO Once Daily N =364 |
EFV/FTC/ TDF Once Daily N=364 |
|
| Nausea | 7% | 8% | 5% | 7% |
| Headache | 6% | 3% | 4% | 5% |
| Fatigue | 6% | 3% | 4% | 4% |
| Diarrhea | 6% | 13% | 4% | 6% |
| Abdominal Pain | 5% | 2% | 1% | 2% |
| Dizziness | 3% | 2% | 7% | 32% |
| Rash | 2% | 3% | 2% | 12% |
| Abnormal Dreams | 1% | <1% | 5% | 10% |
| Insomnia | 1% | 2% | 4% | 5% |
| Somnolence | 0% | <1% | 3% | 7% |
| NRTIs = FTC/TDF or ABC/3TC. Fatigue: includes fatigue, asthenia, malaise Abdominal Pain: includes abdominal discomfort, abdominal pain, abdominal pain lower, abdominal pain upper, epigastric discomfort Rash: includes rash, rash erythematous, rash generalized, rash macular, rash maculo-papular, rash papular, rash pruritic, rash pustular * Frequencies of adverse reactions are based on all adverse events attributed to trial drugs by the investigator. † No adverse reactions of Grade 2 or higher (moderate or severe) occurred in ≥ 2% of participants treated with doravirine. ‡ NRTI = nucleoside reverse transcriptase inhibitor. |
||||
The majority (77%) of adverse reactions associated with doravirine occurred at severity Grade 1 (mild).
For DRIVE-AHEAD, the analysis of participants with neuropsychiatric adverse events by Week 48 is presented in Table 2. The proportion of participants who reported one or more neuropsychiatric adverse events was 24% and 57% in the DELSTRIGO and EFV/FTC/TDF groups, respectively.
A statistically significantly lower proportion of DELSTRIGO-treated participants compared to EFV/FTC/TDF-treated participants reported neuropsychiatric adverse events by Week 48 in the three pre-specified categories of dizziness, sleep disorders and disturbances, and altered sensorium.
Table 2: DRIVE-AHEAD - Analysis of Participants with Neuropsychiatric Adverse Events* (Week 48)
| DELSTRIGO Once Daily N=364 |
EFV/FTC/TDF Once Daily N=364 |
Treatment Difference DELSTRIGO -EFV/FTC/TDF Estimate (95% CI)† | |
| Sleep disorders and disturbances‡ | 12% | 26% | -13.5 (-19.1, -7.9) |
| Dizziness | 9% | 37% | -28.3 (-34.0, -22.5) |
| Altered sensorium§ | 4% | 8% | -3.8 (-7.6, -0.3) |
| *All causality and all grade events were included in the analysis. †The 95% CIs were calculated using Miettinen and Nurminen's method. Categories prespecified for statistical testing were dizziness (p <0.001), sleep disorders and disturbances (p <0.001), and altered sensorium (p=0.033). ‡ Predefined using MedDRA preferred terms, including: abnormal dreams, hyposomnia, initial insomnia, insomnia, nightmare, sleep disorder, somnambulism. §Predefined using MedDRA preferred terms, including: altered state of consciousness, lethargy, somnolence, syncope. |
|||
Neuropsychiatric adverse events in the pre-defined category of depression and suicide/self-injury were reported in 4% and 7% of participants, in the DELSTRIGO and EFV/FTC/TDF groups, respectively.
In DRIVE-AHEAD through 48 weeks of treatment, the majority of participants who reported neuropsychiatric adverse events reported events that were mild to moderate in severity (97% [83/86] and 96% [198/207], in the DELSTRIGO and EFV/FTC/TDF groups, respectively) and the majority of participants reported these events in the first 4 weeks of treatment (72% [62/86] in the DELSTRIGO group and 86% [177/207] in the EFV/FTC/TDF group).
Neuropsychiatric adverse events led to treatment discontinuation in 1% (2/364) and 1% (5/364) of participants in the DELSTRIGO and EFV/FTC/TDF groups, respectively. The proportion of participants who reported neuropsychiatric adverse events through Week 4 was 17% (62/364) in the DELSTRIGO group and 49% (177/364) in the EFV/FTC/TDF group. At Week 48, the prevalence of neuropsychiatric adverse events was 12% (44/364) in the DELSTRIGO group and 22% (81/364) in the EFV/FTC/TDF group. At Week 96, the prevalence of neuropsychiatric adverse events was 13% (47/364) in the DELSTRIGO group and 23% (82/364) in the EFV/FTC/TDF group.
The percentages of participants with selected laboratory abnormalities (that represent a worsening from baseline) who were treated with PIFELTRO or DRV+r in DRIVEFORWARD, or DELSTRIGO or EFV/FTC/TDF in DRIVE-AHEAD are presented in Table 3.
Table 3: Selected Laboratory Abnormalities Reported in Adult Participants with No Antiretroviral Treatment History in DRIVEFORWARD and DRIVE-AHEAD (Week 96)
| Laboratory Parameter Preferred Term(Unit)/Limit | DRIVE-FORWARD | DRIVE-AHEAD | ||
| PIFELTRO + 2 NRTIs Once Daily N=383 |
DRV+r+2 NRTIs Once Daily N=383 |
DELSTRIGO Once Daily N=364 |
EFV/FTC/ TDF Once Daily N=364 |
|
| Blood Chemistry | ||||
| Total bilirubin (mg/dL) | ||||
| 1.1 - < 1.6 x ULN | 6% | 2% | 5% | 0% |
| 1.6 - <2.6 x ULN | 2% | <1% | 2% | 0% |
| ≥2.6 x ULN | <1% | 0% | 1% | <1% |
| Creatinine (mg/dL) | ||||
| >1.3 - 1.8 x ULN or Increase of >0.3 mg/dL above baseline | 4% | 6% | 3% | 2% |
| >1.8 x ULN or Increase of ≥1.5 x above baseline | 4% | 4% | 3% | 2% |
| Aspartate aminotransferase (IU/L) | ||||
| 2.5 - <5.0 x ULN | 5% | 4% | 3% | 3% |
| ≥5.0 x ULN | 2% | 2% | 1% | 4% |
| Alanine aminotransferase (IU/L) | ||||
| 2.5 - <5.0 x ULN | 4% | 2% | 4% | 4% |
| ≥5.0 x ULN | 2% | 3% | 1% | 3% |
| Alkaline phosphatase (IU/L) | ||||
| 2.5 - <5.0 x ULN | <1% | 1% | <1% | 1% |
| ≥5.0 x ULN | 0% | <1% | 0% | <1% |
| Lipase | ||||
| 1.5 - <3.0 x ULN | 7% | 6% | 6% | 4% |
| ≥3.0 x ULN | 3% | 4% | 2% | 3% |
| Creatine kinase (IU/L) | ||||
| 6.0 - <10.0 x ULN | 3% | 3% | 3% | 3% |
| ≥10.0 x ULN | 5% | 6% | 4% | 6% |
| Cholesterol, fasted (mg/dL) | ||||
| ≥300 mg/dL | 0% | 1% | 1% | <1% |
| LDL cholesterol, fasted (mg/dL) | ||||
| ≥190 mg/dL | <1% | 4% | <1% | 2% |
| Triglycerides, fasted (mg/dL) | ||||
| >500 mg/dL | 1% | 2% | 1% | 3% |
| Each participant is only counted once per parameter at the highest toxicity grade. Only participants with a baseline value and at least one on-treatment value for a given laboratory parameter are included. ULN = Upper limit of normal range. Note: NRTIs = FTC/TDF or ABC/3TC. |
||||
For DRIVE-FORWARD and DRIVE-AHEAD, changes from baseline at Week 48 in LDLcholesterol, non-HDL-cholesterol, total cholesterol, triglycerides, and HDL-cholesterol are shown in Table 4. Changes from baseline at Week 96 were similar to those seen at Week 48.
The LDL and non-HDL comparisons were pre-specified and are summarized in Table 4. The differences were statistically significant, showing superiority for doravirine for both parameters. The clinical benefit of these findings has not been demonstrated.
Table 4: Mean Change from Baseline in Fasting Lipids in Adult Participants with No Antiretroviral Treatment History in DRIVEFORWARD and DRIVE-AHEAD (Week 48)
| DRIVE-FORWARD | |||||
| Laboratory Parameter Preferred Term | PIFELTRO + 2 NRTIs Once Daily N=320 |
DRV+r+2 NRTIs Once Daily N=311 |
Difference Estimates (95% CI) | ||
| Baseline | Change | Baseline | Change | ||
| LDL-Cholesterol (mg/dL)* | 91.4 | -4.6 | 92.3 | 9.5 | -14.4 (-18.0, -10.8) |
| Non-HDL Cholesterol (mg/dL)* | 113.6 | -5.4 | 114.5 | 13.7 | -19.4 (-23.4, -15.4) |
| Total Cholesterol (mg/dL)† | 157.2 | -1.4 | 157.8 | 18.0 | - |
| Triglycerides (mg/dL)† | 111.0 | -3.1 | 113.7 | 24.5 | - |
| HDL- Cholesterol (mg/dL)† | 43.6 | 4.0 | 43.3 | 4.3 | - |
| DRIVE-AHEAD | |||||
| Laboratory Parameter Preferred Term | DELSTRIGO Once Daily N=320 |
EFV/FTC/TDF Once Daily N=307 |
Difference Estimates (95% CI) | ||
| Baseline | Change | Baseline | Change | ||
| LDL-Cholestero (mg/dL)* | 91.7 | -2.1 | 91.3 | 8.3 | -10.2 (-13.8, -6.7) |
| Non-HDL Cholesterol (mg/dL)* | 114.7 | -4.1 | 115.3 | 12.7 | -16.9 (-20.8, -13.0) |
| Total Cholesterol (mg/dL)† | 156.8 | -2.2 | 156.8 | 21.1 | - |
| Triglycerides (mg/dL)† | 118.7 | -12.0 | 122.6 | 21.6 | - |
| HDL- Cholesterol (mg/dL)† | 42.1 | 1.8 | 41.6 | 8.4 | - |
| Participants on lipid-lowering agents at baseline were excluded from these analyses (in DRIVE-FORWARD: PIFELTRO n=12 and DRV+r n=14; in DRIVEAHEAD: DELSTRIGO n=15 and EFV/FTC/TDF n=10). Participants initiating a lipid-lowering agent post-baseline had their last fasted on-treatment value (prior to starting the agent) carried forward (in DRIVE-FORWARD: PIFELTRO n=6 and DRV+r n=4; in DRIVE-AHEAD: DELSTRIGO n=3 and EFV/FTC/TDF n=8). * p-values for the pre-specified hypothesis testing for treatment difference were <0.0001 in both DRIVE-FORWARD and DRIVE-AHEAD. † Not pre-specified for hypothesis testing. |
|||||
Adverse Reactions In Virologically-Suppressed Adults
The safety of DELSTRIGO in virologically-suppressed adults was based on Week 48 data from 670 participants in the DRIVE-SHIFT trial (Protocol 024), a randomized, international, multicenter, open-label trial in which virologically-suppressed participants were switched from a baseline regimen consisting of two NRTIs in combination with a protease inhibitor (PI) plus either ritonavir or cobicistat, or elvitegravir plus cobicistat, or a non-nucleoside reverse transcriptase inhibitor (NNRTI) to DELSTRIGO. Overall, the safety profile in virologically-suppressed adult participants was similar to that in participants with no antiretroviral treatment history.
Serum ALT And AST Elevations
In the DRIVE-SHIFT trial, 22% and 16% of participants in the immediate switch group experienced ALT and AST elevations greater than 1.25 × ULN, respectively, through 48 weeks on DELSTRIGO. For these ALT and AST elevations, no apparent patterns with regard to time to onset relative to switch were observed. One percent of participants had ALT or AST elevations greater than 5 × ULN through 48
weeks on DELSTRIGO. The ALT and AST elevations were generally asymptomatic and not associated with bilirubin elevations. In comparison, 4% and 4% of participants in the delayed switch group experienced ALT and AST elevations of greater than 1.25 × ULN through 24 weeks on their baseline regimen.
Changes from baseline at Week 24 in LDL-cholesterol, non-HDL-cholesterol, total cholesterol, triglycerides, and HDL-cholesterol in participants on a PI plus ritonavir-based regimen at baseline are shown in Table 5. The LDL and non-HDL comparisons were prespecified, and the differences were statistically significant, showing superiority for an immediate switch to DELSTRIGO for both parameters. The clinical benefit of these findings has not been demonstrated.
Table 5: Mean Change from Baseline in Fasting Lipids in Adult Virologically-Suppressed Participants on a PI plus Ritonavir-based Regimen at Baseline in DRIVE-SHIFT (Week 24)
| Laboratory Parameter Preferred Term | DELSTRIGO (Week 0-24) Once Daily N=244 |
PI+ritonavir (Week 0-24) Once Daily N=124 |
Difference Estimates | ||
| Baseline | Change | Baseline | Change | Difference (95% CI) | |
| LDL-Cholesterol (mg/dL)* | 108.7 | -16.3 | 110.5 | -2.6 | -14.5 (-18.9, -10.1) |
| Non-HDL Cholesterol (mg/dL)* | 138.6 | -24.8 | 138.8 | -2.1 | -22.8 (-27.9, -17.7) |
| Total Cholesterol (mg/dL)† | 188.5 | -26.1 | 187.4 | -0.2 | - |
| Triglycerides (mg/dL)† | 153.1 | -44.4 | 151.4 | -0.4 | - |
| HDL-Cholesterol (mg/dL)† | 50.0 | -1.3 | 48.5 | 1.9 | - |
| Participants on lipid-lowering agents at baseline were excluded from these analyses (DELSTRIGO n=26 and PI+ritonavir n=13). Participants initiating a lipid-lowering agent post-baseline had their last fasted on-treatment value (prior to starting the agent) carried forward (DELSTRIGO n=4 and PI+ritonavir n=2). * p-value for the pre-specified hypothesis testing for treatment difference was <0.0001. †Not pre-specified for hypothesis testing. |
|||||
Adverse Reactions In Pediatric Participants
The safety of doravirine as a component of DELSTRIGO was evaluated in 45 virologicallysuppressed or treatment-naïve pediatric participants 12 to less than 18 years of age living with HIV through Week 24 in an open-label trial (IMPAACT 2014 (Protocol 027)) [see Clinical Studies]. The safety profile in pediatric participants was similar to that in adults. There were no serious or Grade 3 or 4 adverse reactions. No participants discontinued due to an adverse event.
The following adverse reactions have been identified during postmarketing experience in patients receiving doravirine-containing regimens. Because postmarketing reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Skin and Subcutaneous Tissue Disorders: Stevens-Johnson syndrome (SJS)/toxic epidermal necrolysis (TEN)
Co-administration of PIFELTRO with a CYP3A inducer decreases doravirine plasma concentrations, which may reduce PIFELTRO efficacy [see CONTRAINDICATIONS, WARNINGS AND PRECAUTIONS, and CLINICAL PHARMACOLOGY]. Co-administration of PIFELTRO and drugs that are inhibitors of CYP3A may result in increased plasma concentrations of doravirine.
Table 6 shows significant drug interactions with PIFELTRO.
Table 6: Drug Interactions with PIFELTRO*
| Concomitant Drug Class: Drug Name | Effect on Concentration | Clinical Comment |
| Androgen Receptors | ||
| enzalutamide | ↓ doravirine | Co-administration is contraindicated with enzalutamide. At least a 4-week cessation period is recommended prior to initiation of PIFELTRO. |
| Anticonvulsants | ||
| carbamazepine oxcarbazepine phenobarbital phenytoin |
↓ doravirine | Co-administration is contraindicated with these anticonvulsants. At least a 4-week cessation period is recommended prior to initiation of PIFELTRO. |
| Antimycobacterials | ||
| rifampin† rifapentine |
↓ doravirine | Co-administration is contraindicated with rifampin or rifapentine. At least a 4-week cessation period is recommended prior to initiation of PIFELTRO. |
| rifabutin† | ↓ doravirine | Increase PIFELTRO dosage to one tablet twice daily when co-administered with rifabutin [see DOSAGE AND ADMINISTRATION]. |
| Cytotoxic Agents | ||
| mitotane | ↓doravirine | Co-administration is contraindicated with mitotane. At least a 4-week cessation period is recommended prior to initiation of PIFELTRO. |
| HIV Antiviral Agents | ||
| efavirenz† etravirine nevirapine Herbal Products |
↓doravirine | Use with efavirenz, etravirine, or nevirapine is not recommended. |
| St. John's wort | ↓ doravirine | Co-administration is contraindicated with St. John's wort. At least a 4-week cessation period is recommended prior to initiation of PIFELTRO. |
| ↑ = increase, ↓ = decrease All other drug-drug interactions shown are anticipated based on the known metabolic and elimination pathways. *This table is not all inclusive. †The interaction between PIFELTRO and the concomitant drug was evaluated in a clinical study. |
||
No clinically significant changes in concentration were observed for doravirine when coadministered with the following agents: dolutegravir, TDF, lamivudine, elbasvir and grazoprevir, ledipasvir and sofosbuvir, ritonavir, ketoconazole, aluminum hydroxide/magnesium hydroxide/simethicone containing antacid, pantoprazole, and methadone [see CLINICAL PHARMACOLOGY].
No clinically significant changes in concentration were observed for the following agents when co-administered with doravirine: dolutegravir, lamivudine, TDF, elbasvir and grazoprevir, ledipasvir and sofosbuvir, atorvastatin, an oral contraceptive containing ethinyl estradiol and levonorgestrel, metformin, methadone, and midazolam [see CLINICAL PHARMACOLOGY].
Included as part of the PRECAUTIONS section.
Severe skin reactions, including Stevens-Johnson syndrome (SJS)/toxic epidermal necrolysis (TEN), have been reported during the postmarketing experience with doravirine-containing regimens [see ADVERSE REACTIONS]. Discontinue PIFELTRO, and other medications known to be associated with severe skin reactions, immediately if a painful rash with mucosal involvement or a progressive severe rash develops. Clinical status should be closely monitored, and appropriate therapy should be initiated.
The concomitant use of PIFELTRO and certain other drugs may result in known or potentially significant drug interactions, some of which may lead to loss of therapeutic effect of PIFELTRO and possible development of resistance [see DOSAGE AND ADMINISTRATION, CONTRAINDICATIONS and DRUG INTERACTIONS].
See Table 6 for steps to prevent or manage these possible and known significant drug interactions, including dosing recommendations. Consider the potential for drug interactions prior to and during PIFELTRO therapy, review concomitant medications during PIFELTRO therapy, and monitor for adverse reactions.
Immune reconstitution syndrome has been reported in patients treated with combination antiretroviral therapy. During the initial phase of combination antiretroviral treatment, patients whose immune system responds may develop an inflammatory response to indolent or residual opportunistic infections (such as Mycobacterium avium infection, cytomegalovirus, Pneumocystis jirovecii pneumonia (PCP), or tuberculosis), which may necessitate further evaluation and treatment.
Autoimmune disorders (such as Graves' disease, polymyositis, Guillain-Barré syndrome, and autoimmune hepatitis) have also been reported to occur in the setting of immune reconstitution; however, the time to onset is more variable and can occur many months after initiation of treatment.
Advise the patient to read the FDA-approved patient labeling (PATIENT INFORMATION).
Inform patients that severe skin reactions including Stevens-Johnson syndrome (SJS)/toxic epidermal necrolysis (TEN) have been reported with PIFELTRO. Advise patients to immediately contact their healthcare provider if they develop a rash. Instruct patients to immediately stop taking PIFELTRO and seek medical attention if a painful rash with mucosal involvement develops [see WARNINGS AND PRECAUTIONS].
Inform patients that PIFELTRO may interact with certain other drugs; therefore, advise patients to report to their healthcare provider the use of any other prescription or nonprescription medication or herbal products, including St. John's wort [see CONTRAINDICATIONS, WARNINGS AND PRECAUTIONS, and DRUG INTERACTIONS].
For patients concomitantly receiving rifabutin, take one tablet of PIFELTRO twice daily (approximately 12 hours apart) [see DOSAGE AND ADMINISTRATION].
Inform patients that in some patients with advanced HIV infection (AIDS), signs and symptoms of inflammation from previous infections may occur soon after anti-HIV treatment is started. It is believed that these symptoms are due to an improvement in the body's immune response, enabling the body to fight infections that may have been present with no obvious symptoms. Advise patients to inform their healthcare provider immediately of any symptoms of infection [see WARNINGS AND PRECAUTIONS].
Advise patients to take PIFELTRO every day at a regularly scheduled time with or without food. Inform patients that it is important not to miss or skip doses as it can result in development of resistance. If a patient forgets to take PIFELTRO, tell the patient to take the missed dose right away, unless it is almost time for the next dose. Advise the patient not to take 2 doses at one time and to take the next dose at the regularly scheduled time.
Inform patients that there is an antiretroviral pregnancy registry to monitor fetal outcomes in pregnant individuals exposed to PIFELTRO [see Use In Specific Populations].
Inform individuals with HIV-1 infection that the potential risks of breastfeeding include: (1) HIV-1 transmission (in HIV-1–negative infants), (2) developing viral resistance (in HIV- 1– positive infants), and (3) serious adverse reactions in a breastfed infant similar to those seen in adults [see Use In Specific Populations].
Doravirine was not carcinogenic in long-term oral carcinogenicity studies in mice and rats at exposures up to 6 and 7 times, respectively, the human exposures at the RHD. A statistically significant incidence of thyroid parafollicular cell adenoma and carcinoma seen only in female rats at the high dose was within the range observed in historical controls.
Doravirine was not genotoxic in a battery of in vitro or in vivo assays, including microbial mutagenesis, chromosomal aberration in Chinese hamster ovary cells, and in in vivo rat micronucleus assays.
There were no effects on fertility, mating performance or early embryonic development when doravirine was administered to rats at systemic exposures (AUC) approximately 7 times the exposure in humans at the RHD.
There is a pregnancy exposure registry that monitors pregnancy outcomes in individuals exposed to PIFELTRO during pregnancy. Healthcare providers are encouraged to register patients by calling the Antiretroviral Pregnancy Registry (APR) at 1-800-258- 4263.
No adequate human data are available to establish whether or not PIFELTRO poses a risk to pregnancy outcomes. In animal reproduction studies, no adverse developmental effects were observed when doravirine was administered at exposures ≥8 times the exposure in humans at the recommended human dose (RHD) of PIFELTRO (see Data).
The background rate of major birth defects is 2.7% in a U.S. reference population of the Metropolitan Atlanta Congenital Defects Program (MACDP). The rate of miscarriage is not reported in the APR. The estimated background rate of miscarriage in the clinically recognized pregnancies in the U.S. general population is 15-20%. Methodological limitations of the APR include the use of MACDP as the external comparator group. The MACDP population is not disease-specific, evaluates individuals and infants from the limited geographic area, and does not include outcomes for births that occurred at less than 20 weeks gestation.
Animal Data
Doravirine was administered orally to pregnant rabbits (up to 300 mg/kg/day on gestation days (GD) 7 to 20) and rats (up to 450 mg/kg/day on GD 6 to 20 and separately from GD 6 to lactation/postpartum day 20). No significant toxicological effects on embryo-fetal (rats and rabbits) or pre/post-natal (rats) development were observed at exposures (AUC) approximately 9 times (rats) and 8 times (rabbits) the exposure in humans at the RHD. Doravirine was transferred to the fetus through the placenta in embryo-fetal studies, with fetal plasma concentrations of up to 40% (rabbits) and 52% (rats) that of maternal concentrations observed on GD 20.
It is unknown whether doravirine is present in human milk, affects human milk production, or has effects on the breastfed infant. Doravirine is present in the milk of lactating rats (see Data). Potential risks of breastfeeding include: (1) HIV-1 transmission (in HIV-1-negative infants), (2) developing viral resistance (in HIV-1-positive infants), and (3) serious adverse reactions in a breastfed infant in a breastfed infant similar to those seen in adults.
Doravirine was excreted into the milk of lactating rats following oral administration (450 mg/kg/day) from GD 6 to lactation day 14, with milk concentrations approximately 1.5 times that of maternal plasma concentrations observed 2 hours post dose on lactation day 14.
The safety and efficacy of PIFELTRO for the treatment of HIV-1 infection have been established in pediatric patients weighing at least 35 kg [see INDICATIONS AND USAGE and DOSAGE AND ADMINISTRATION].
Use of PIFELTRO in this group is supported by evidence from adequate and wellcontrolled trials in adults and an open-label trial in virologically-suppressed or treatmentnaïve pediatric participants 12 to less than 18 years of age. The safety, efficacy, and exposure of doravirine in these pediatric participants were similar to that in adults [see ADVERSE REACTIONS, CLINICAL PHARMACOLOGY, and Clinical Studies].
Safety and efficacy of PIFELTRO in pediatric patients weighing less than 35 kg have not been established.
Clinical trials of PIFELTRO did not include sufficient numbers of participants aged 65 years and over to determine whether they respond differently from younger participants. In general, caution should be exercised in the administration of PIFELTRO in elderly patients, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy [see CLINICAL PHARMACOLOGY].
No dosage adjustment of PIFELTRO is required in patients with mild, moderate, or severe renal impairment. PIFELTRO has not been adequately studied in patients with end-stage renal disease and has not been studied in dialysis patients [see CLINICAL PHARMACOLOGY].
No dosage adjustment of PIFELTRO is required in patients with mild (Child-Pugh Class A) or moderate (Child-Pugh Class B) hepatic impairment. PIFELTRO has not been studied in patients with severe hepatic impairment (Child-Pugh Class C) [see CLINICAL PHARMACOLOGY].
No Information provided
PIFELTRO is contraindicated when co-administered with drugs that are strong cytochrome P450 (CYP)3A enzyme inducers as significant decreases in doravirine plasma concentrations may occur, which may decrease the effectiveness of PIFELTRO [see WARNINGS AND PRECAUTIONS, DRUG INTERACTIONS, and CLINICAL PHARMACOLOGY]. These drugs include, but are not limited to, the following:
Doravirine is an antiretroviral drug [see Microbiology].
In a Phase 2 trial evaluating doravirine over a dose range of 0.25 to 2 times the recommended dose of PIFELTRO, (in combination with FTC/TDF) in participants living with HIV with no antiretroviral treatment history, no exposure-response relationship for efficacy was identified for doravirine.
At a doravirine dose of 1200 mg, which provides approximately 4 times the peak concentration observed following the recommended dose of PIFELTRO, doravirine does not prolong the QT interval to any clinically relevant extent.
Doravirine pharmacokinetics are similar in healthy participants and participants living with HIV. Doravirine pharmacokinetics are provided in Table 7.
Table 7: Pharmacokinetic Properties of Doravirine
| Parameter | Doravirine |
| General | |
| Steady State Exposure*,† | |
| AUC0-24 (mcg•h/mL) | 16.1 (29) |
| Cmax (mcg/mL) | 0.962 (19) |
| C24 (mcg/mL) | 0.396 (63) |
| Time to Steady State (Days) | 2 |
| Accumulation Ratio | 1.2 to 1.4 |
| Absorption | |
| Absolute Bioavailability | 64% |
| Tmax (h) | 2 |
| Effect of Food‡ | |
| AUC Ratio | 1.16 (1.06, 1.26) |
| Cmax Ratio | 1.03 (0.89, 1.19) |
| C24 Ratio | 1.36 (1.19, 1.55) |
| Distribution | |
| Vdss (L)§ | 60.5 |
| Plasma Protein Binding | 76% |
| Elimination | |
| t½ (h) | 15 |
| CL/F (mL/min)† | 106 (35.2) |
| CLrenal (mL/min)† | 9.3 (18.6) |
| Metabolism | |
| Primary Pathway(s) | CYP3A |
| Excretion | |
| Major Route of Elimination | Metabolism |
| Urine (unchanged) | 6% |
| Biliary/Fecal (unchanged) | Minor |
| Abbreviations: AUC=area under the time concentration curve; C max=maximum concentration; C24=concentration at 24 hours; Tmax time to Cmax ; Vdss = volume of distribution at steady state, t½=elimination half-life; CL/F=apparent clearance; CLrenal =apparent renal clearance *Doravirine 100 mg once daily to participants living with HIV †Presented as geometric mean (%CV: geometric coefficient of variation) ‡Geometric mean ratio [high-fat meal/fasting] and (90% confidence interval) for PK parameters. High fat meal is approximately 1,000 kcal, 50% fat. The effect of food is not clinically relevant. §Based on IV dose |
|
In adults, no clinically significant difference on the pharmacokinetics of doravirine were observed based on age (18 to 78 years of age), sex, and race/ethnicity, mild to severe renal impairment (creatinine clearance (CLcr) >15 mL/min, estimated by Cockcroft- Gault), or moderate hepatic impairment (Child-Pugh B). The pharmacokinetics of doravirine in patients with end-stage renal disease or undergoing dialysis, or severe hepatic impairment (Child-Pugh C) is unknown.
In a study comparing 8 participants with severe renal impairment to 8 participants without renal impairment, the single dose exposure of doravirine was 43% higher in participants with severe renal impairment. In a population pharmacokinetic analysis, renal function did not have a clinically relevant effect on doravirine pharmacokinetics. Doravirine has not been studied in patients with end-stage renal disease or in patients undergoing dialysis [see Use In Specific Populations].
No clinically significant difference in the pharmacokinetics of doravirine was observed in participants with moderate hepatic impairment (Child-Pugh score B) compared to participants without hepatic impairment. Doravirine has not been studied in participants with severe hepatic impairment (Child-Pugh score C) [see Use In Specific Populations].
Mean doravirine exposures were similar in 54 pediatric participants aged 12 to less than 18 years and weighing at least 35 kg who received doravirine or DELSTRIGO in IMPAACT 2014 (Protocol 027) relative to adults following administration of doravirine or DELSTRIGO (Table 8). For pediatric participants weighing ≥ 35 kg and < 45 kg who received doravirine 100 mg or DELSTRIGO, the population pharmacokinetic modelpredicted mean C24 of doravirine was comparable to that achieved in adults, whereas mean AUC0-24 and Cmax of doravirine were 25% and 36% higher than adult values, respectively. However, the predicted AUC0-24 and Cmax increases are not considered clinically significant.
Table 8: Steady State Pharmacokinetics for Doravirine Following Administration of Doravirine or DELSTRIGO in Pediatric Participants Living with HIV Aged 12 to Less than 18 Years and Weighing at Least 35 kg
| Parameter* | Doravirine† |
| AUC0-24 (mcg•h/mL) | 16.4 (24) |
| Cmax (mcg/mL) | 1.03 (16) |
| C24 (mcg/mL) | 0.379 (42) |
| Abbreviations: AUC=area under the time concentration curve; Cmax =maximum concentration; C24 =concentration at 24 hours * Presented as geometric mean (%CV: geometric coefficient of variation) † From population PK analysis (n=53 weighing ≥45 kg, n=1 weighing ≥35 kg to <45 kg) |
|
Doravirine is primarily metabolized by CYP3A, and drugs that induce or inhibit CYP3A may affect the clearance of doravirine. Co-administration of doravirine and drugs that induce CYP3A may result in decreased plasma concentrations of doravirine. Co- administration of doravirine and drugs that inhibit CYP3A may result in increased plasma concentrations of doravirine.
Doravirine is not likely to have a clinically relevant effect on the exposure of medicinal products metabolized by CYP enzymes. Doravirine did not inhibit major drug metabolizing enzymes in vitro, including CYPs 1A2, 2B6, 2C8, 2C9, 2C19, 2D6, 3A4, and UGT1A1 and is not likely to be an inducer of CYP1A2, 2B6, or 3A4. Based on in vitro assays, doravirine is not likely to be an inhibitor of OATP1B1, OATP1B3, P-glycoprotein, BSEP, OAT1, OAT3, OCT2, MATE1, and MATE2K. Drug interaction studies were performed with doravirine and other drugs likely to be co-administered or commonly used as probes for pharmacokinetic interactions. The effects of co-administration with other drugs on the exposure (Cmax, AUC, and C24) of doravirine are summarized in Table 9. A single doravirine 100 mg dose was administered in these studies unless otherwise noted.
Table 9: Drug Interactions: Changes in Pharmacokinetic Parameter Values of Doravirine in the Presence of Co-administered Drug
| Co- administered Drug | Regimen of Coadministered Drug | N | Geometric Mean Ratio (90% CI) of Doravirine Pharmacokinetics with/without Co-administered Drug (No Effect=1.00) | ||
| AUC* | Cmax | C24 | |||
| Azole Antifungal Agents | |||||
| ketoconazole† | 400 mg QD | 10 | 3.06 (2.85, 3.29) |
1.25 (1.05, 1.49) |
2.75 (2.54, 2.98) |
| Antimycobacterials | |||||
| rifampin | 600 mg QD | 10 | 0.12 (0.10, 0.15) |
0.43 (0.35, 0.52) |
0.03 (0.02, 0.04) |
| rifabutin | 300 mg QD | 12 | 0.50 (0.45, 0.55) |
0.99 (0.85, 1.15) |
0.32 (0.28, 0.35) |
| 300 mg QD‡ | 15 | 1.03 (0.94, 1.14) |
0.97 (0.87, 1.08) |
0.98 (0.88, 1.10) |
|
| HIV Antiviral Agents | |||||
| ritonavir†,§ | 100 mg BID | 8 | 3.54 (3.04, 4.11) |
1.31 (1.17, 1.46) |
2.91 (2.33, 3.62) |
| efavirenz | 600 mg QD¶ | 17 | 0.38 (0.33, 0.45) |
0.65 (0.58, 0.73) |
0.15 (0.10, 0.23) |
| 600 mg QD# | 17 | 0.68 (0.58, 0.80) |
0.86 (0.77, 0.97) |
0.50 (0.39, 0.64) |
|
| CI = confidence interval; QD = once daily; BID = twice daily *AUC for single-dose, 0-∞ AUC0-24 for once daily. †Changes in doravirine pharmacokinetic values are not clinically relevant. ‡Doravirine 100 mg BID resulted in similar pharmacokinetic values when compared to 100 mg QD without rifabutin. §A single doravirine 50 mg dose (0.5 times the recommended approved dose) was administered. ¶The first day following the cessation of efavirenz therapy and initiation of doravirine 100 mg QD. # 14 days following the cessation of efavirenz therapy and initiation of doravirine 100 mg QD. |
|||||
Based on drug interaction studies conducted with doravirine, no clinically significant drug interactions have been observed following the co-administration of doravirine and the following drugs: dolutegravir, ritonavir, TDF, lamivudine, elbasvir and grazoprevir, ledipasvir and sofosbuvir, ketoconazole, aluminum hydroxide/magnesium hydroxide/simethicone containing antacid, pantoprazole, atorvastatin, an oral contraceptive containing ethinyl estradiol and levonorgestrel, metformin, methadone, and midazolam.
Doravirine is a pyridinone non-nucleoside reverse transcriptase inhibitor of HIV-1 and inhibits HIV-1 replication by non-competitive inhibition of HIV-1 reverse transcriptase (RT). The inhibitory concentration at 50% (IC50) of doravirine for RNA-dependent DNA polymerization of recombinant wild-type HIV-1 RT in a biochemical assay was 12.2±2.0 nM (n=3). Doravirine does not inhibit the human cellular DNA polymerases α, β, and mitochondrial DNA polymerase γ.
Doravirine exhibited an EC50 value of 12.0±4.4 nM against wild-type laboratory strains of HIV-1 when tested in the presence of 100% normal human serum (NHS) using MT4-GFP reporter cells and a median EC50 value for HIV-1 subtype B primary isolates (n=118) of 4.1 nM (range: 1.0 nM-16.0 nM). Doravirine demonstrated antiviral activity against a broad panel of primary HIV-1 isolates (A, A1, AE, AG, B, BF, C, D, G, H) with EC50 values ranging from 1.2 nM to 10.0 nM.
The antiviral activity of doravirine in cell culture was not antagonistic when combined with the NNRTIs delavirdine, efavirenz, etravirine, nevirapine, or rilpivirine; the NRTIs abacavir, didanosine, emtricitabine, lamivudine, stavudine, tenofovir DF, or zidovudine; the PIs darunavir or indinavir; the gp41 fusion inhibitor enfuvirtide; the CCR5 co-receptor antagonist maraviroc; or the integrase strand transfer inhibitor raltegravir.
In Cell Culture
Doravirine-resistant strains were selected in cell culture starting from wild-type HIV-1 of different origins and subtypes, as well as NNRTI-resistant HIV-1. Observed emergent amino acid substitutions in RT included: V106A, V106I, V106M, V108I, H221Y, F227C, F227I, F227L, F227V, M230I, L234I, P236L, and Y318F. The V106A, V106M, V108I, H221Y, F227C, M230I, P236L, and Y318F substitutions conferred 3.4-fold to 70-fold reductions in susceptibility to doravirine. Y318F in combination with V106A, V106M, V108I, or F227C conferred greater decreases in susceptibility to doravirine than Y318F alone, which conferred a 10-fold reduction in susceptibility to doravirine.
In Clinical Trials
Clinical Trial Results In Adults With No Antiretroviral Treatment History
In the doravirine treatment arms of the DRIVE-FORWARD and DRIVE-AHEAD trials (n=747) through Week 96, 13 participants showed the emergence of doravirine resistance-associated substitutions in their HIV among 36 (36%) participants in the resistance analysis subset (participants with HIV-1 RNA greater than 400 copies per mL at virologic failure or early study discontinuation and having post-baseline resistance samples). Emergent doravirine resistance-associated substitutions in RT included one or more of the following: V90G/I, A98G, V106A, V106I, V106M/T, V108I, E138G, Y188L, H221Y, P225H, P225L, P225P/S, F227C, F227C/R, Y318Y/F and Y318Y/S. Eight of 13 (62%) participants with emergent doravirine resistance-associated substitutions showed doravirine phenotypic resistance and most of them had at least a 100-fold reduction in doravirine susceptibility (range >95- to >211–fold reduction in doravirine susceptibility). The other 5 virologic failures who had only amino acid mixtures of NNRTI resistance substitutions showed doravirine phenotypic fold-changes of less than 2-fold. Of the 36 participants in the resistance analysis subset, 10 participants (28%) developed genotypic and/or phenotypic resistance to the other drugs (abacavir, emtricitabine, lamivudine, or tenofovir) in the regimens of the DRIVE-FORWARD and DRIVE-AHEAD trials. The resistance-associated substitutions that emerged were RT M41L (n=1), A62A/V (n=1), K65R (n=2), T69T/A (n=1), V75V/I (n=1), and M184I or V (n=7).
In the DRV/r treatment arm of the DRIVE-FORWARD trial (n=383) through Week 96, no participants showed the emergence of darunavir resistance-associated substitutions among 15 participants with resistance data and 2 of the participants had emergent genotypic or phenotypic resistance to lamivudine or tenofovir. In the EFV/FTC/TDF treatment arm of the DRIVE-AHEAD trial (n=364) through Week 96, 15 participants showed the emergence of efavirenz resistance-associated substitutions among 25 (60%) participants in the resistance analysis subset and genotypic resistance to emtricitabine or tenofovir developed in 5 evaluable participants; emergent resistanceassociated substitutions were RT K65R (n=1), D67G/K70E (n=1), L74V/V75M/V118I (n=1), M184I or V (n=5), and K219K/E (n=1).
In the DRIVE-SHIFT clinical trial [see Clinical Studies], there were 6 participants in the immediate switch group (n=447) and 2 participants in the delayed switch group (n=209) who met the protocol-defined virologic failure criteria (confirmed HIV-1 RNA ≥ 50 copies/mL). Two of the 6 virologic failure participants in the immediate switch group had available resistance data and neither developed detectable genotypic or phenotypic resistance to doravirine, lamivudine, or tenofovir during treatment with DELSTRIGO. One of the two virologic failure participants in the delayed switch group who had available resistance data developed the RT M184M/I substitution and phenotypic resistance to emtricitabine and lamivudine during treatment with their baseline regimen.
Cross-resistance has been observed among NNRTIs. Treatment-emergent doravirine resistance-associated substitutions can confer cross-resistance to efavirenz, etravirine, nevirapine, and rilpivirine. Of the 8 virologic failure participants who developed doravirine phenotypic resistance, all had phenotypic resistance to nevirapine, 6 had phenotypic resistance to efavirenz, 4 had phenotypic resistance to rilpivirine, and 4 had resistance to etravirine in the Monogram PhenoSense assay. Of the 11 virologic failure participants in DRIVE-AHEAD phenotypically resistant to efavirenz, 2 (18%) had decreased susceptibility to doravirine (18- and 36-fold).
The treatment-emergent doravirine resistance-associated substitution Y318F did not confer reduced susceptibility to efavirenz, etravirine, or rilpivirine.
A panel of 96 diverse clinical isolates containing NNRTI resistance-associated substitutions was evaluated for susceptibility to doravirine. Clinical isolates containing the Y188L substitution alone or in combination with K103N or V106I, V106A in combination with G190A and F227L, or E138K in combination with Y181C and M230L showed greater than 100-fold reduced susceptibility to doravirine.
The efficacy of PIFELTRO is based on the analyses of 96-week data from two randomized, multicenter, double-blind, active controlled Phase 3 trials (DRIVEFORWARD, NCT02275780 and DRIVE-AHEAD, NCT02403674) in participants living with HIV with no antiretroviral treatment history (n=1494).
In DRIVE-FORWARD, 766 participants were randomized and received at least 1 dose of either PIFELTRO once daily or darunavir 800 mg + ritonavir 100 mg (DRV+r) once daily each in combination with emtricitabine/tenofovir DF (FTC/TDF) or abacavir/lamivudine (ABC/3TC) selected by the investigator. At baseline, the median age of participants was 33 years, 16% were female, 27% were Non-White, 4% had hepatitis B and/or C virus coinfection, 10% had a history of AIDS, 20% had HIV-1 RNA greater than 100,000 copies/mL, 86% had CD4+ T-cell count greater than 200 cells/mm³, 13% received ABC/3TC, and 87% received FTC/TDF; these characteristics were similar between treatment groups.
In DRIVE-AHEAD, 728 participants were randomized and received at least 1 dose of either DELSTRIGO (DOR/3TC/TDF) or EFV 600 mg/FTC 200 mg/TDF 300 mg once daily. At baseline, the median age of participants was 31 years, 15% were female, 52% were Non-White, 3% had hepatitis B or C co-infection, 14% had a history of AIDS, 21% had HIV-1 RNA greater than 100,000 copies/mL, and 88% had CD4+ T-cell count greater than 200 cells/mm³; these characteristics were similar between treatment groups.
Week 96 outcomes for DRIVE-FORWARD and DRIVE-AHEAD are provided in Table 10. Side-by-side tabulation is to simplify presentation; direct comparisons across trials should not be made due to differing trial designs.
In DRIVE-FORWARD, the mean CD4+ T-cell counts in the PIFELTRO and DRV+r groups increased from baseline by 224 and 207 cells/mm³, respectively. In DRIVE-AHEAD, the mean CD4+ T-cell counts in the DELSTRIGO and EFV/FTC/TDF groups increased from baseline by 238 and 223 cells/mm , respectively.
Table 10: Virologic Outcome in DRIVE-FORWARD and DRIVE-AHEAD at Week 96 in HIV-1 Adults with No Antiretroviral Treatment History
| Outcome | DRIVE-FORWARD | DRIVE-AHEAD | ||
| PIFELTRO + 2 NRTIs Once Daily N=383 |
DRV+r + 2 NRTIs Once Daily N=383 |
DELSTRIGO Once Daily N=364 |
EFV/FTC/TDF Once Daily N=364 |
|
| HIV-1 RNA <50 copies/mL | 72% | 65% | 77% | 74% |
| Treatment Differences (95% CI) * | 7.5% (1.0%, 14.1%) | 3.8% (-2.4%, 10.0%) | ||
| HIV-1 RNA ≥ 50 copies/mL† | 17% | 20% | 15% | 12% |
| No Virologic Data at Week 96 Window | 11% | 15% | 7% | 14% |
| Discontinued study due to AE or Death‡ | 2% | 4% | 3% | 8% |
| Discontinued study for Other Reasons§ | 7% | 9% | 4% | 5% |
| On study but missing data in window | 2% | 3% | 1% | 1% |
| Proportion (%) of Participants With HIV-1 RNA <50 copies/mL at Week 96 by Baseline and Demographic Category | ||||
| Gender | ||||
| Male | 72% (N = 319) | 67% (N = 326) | 78% (N = 305) | 73% (N = 311) |
| Female | 73% (N = 64) | 54% (N = 57) | 75% (N = 59) | 75% (N = 53) |
| Race | ||||
| White | 78% (N = 280) | 68% (N = 280) | 80% (N = 176) | 74% (N = 170) |
| Non-White | 58% (N = 103) | 57% (N = 102) | 76% (N = 188) | 74% (N = 194) |
| Ethnicity¶ | ||||
| Hispanic or Latino | 76% (N = 93) | 63% (N = 86) | 81% (N = 126) | 77% (N = 119) |
| Not Hispanic or Latino | 71% (N = 284) | 66% (N = 290) | 76% (N = 238) | 72% (N = 239) |
| NRTI Background Therapy | ||||
| FTC/TDF | 71% (N = 333) | 64% (N = 335) | - | - |
| ABC/3TC | 80% (N = 50) | 67% (N = 48) | - | - |
| Baseline HIV-1 RNA (copies/mL) | ||||
| ≤100,000 copies/mL | 75% (N = 300) | 66% (N = 309) | 80% (N = 291) | 77% (N = 282) |
| >100,000 copies/mL | 61% (N = 83) | 59% (N = 73) | 67% (N = 73) | 62% (N = 82) |
| CD4+ T-cell Count (cells/mm³) | ||||
| ≤200 cells/mm³ | 62% (N = 42) | 51% (N = 67) | 59% (N = 44) | 70% (N = 46) |
| >200 cells/mm³ | 74% (N = 341) | 68% (N = 316) | 80% (N = 320) | 74% (N = 318) |
| Viral Subtype¶ | ||||
| Subtype B | 71% (N = 266) | 66% (N = 272) | 80% (N = 232) | 72% (N = 253) |
| Subtype Non-B | 75% (N = 117) | 62% (N = 111) | 73% (N = 130) | 77% (N = 111) |
| Note: NRTIs = FTC/3TC or ABC/3TC. *The 95% CIs for the treatment differences were calculated using stratum-adjusted Mantel- Haenszel method. † Includes participants who discontinued study drug or study before Week 96 for lack or loss of efficacy and participants with HIV-1 RNA equal to or above 50 copies/mL in the Week 96 window. ‡ Includes participants who discontinued because of adverse event (AE) or death if this resulted in no virologic data in the Week 96 window. § Other Reasons include: lost to follow-up, non-compliance with study drug, physician decision, pregnancy, protocol deviation, screen failure, withdrawal by participant. ¶ Does not include participants whose ethnicity or viral subtypes were unknown. |
||||
The efficacy of switching from a baseline regimen consisting of two NRTIs in combination with a PI plus either ritonavir or cobicistat, or elvitegravir plus cobicistat, or an NNRTI to DELSTRIGO was evaluated in a randomized, open-label trial (DRIVE-SHIFT, NCT02397096), in virologically-suppressed adultsliving with HIV. Participants must have been virologically-suppressed (HIV-1 RNA < 50 copies/mL) on their baseline regimen for at least 6 months prior to trial entry, with no history of virologic failure. Participants were randomized to either switch to DELSTRIGO at baseline (n = 447, Immediate Switch Group (ISG)), or stay on their baseline regimen until Week 24, at which point they switched to DELSTRIGO (n = 223, Delayed Switch Group (DSG)).
At baseline, the median age of participants was 43 years, 16% were female, and 24% were Non-White, 21% were of Hispanic or Latino ethnicity, 3% had hepatitis B and/or C virus co-infection, 17% had a history of AIDS, 96% had CD4+ T-cell count greater than or equal to 200 cells/mm³, 70% were on a regimen containing a PI plus ritonavir, 24% were on a regimen containing an NNRTI, 6% were on a regimen containing elvitegravir plus cobicistat, and 1% were on a regimen containing a PI plus cobicistat; these characteristics were similar between treatment groups.
Virologic outcome results are shown in Table 11.
Table 11: Virologic Outcomes in DRIVE-SHIFT in HIV-1 Virologically- Suppressed Participants Who Switched to DELSTRIGO
| Outcome | DELSTRIGO Once Daily ISG Week 48 N=447 |
Baseline Regimen DSG Week 24 N=223 |
| HIV-1 RNA ≥ 50 copies/mL* | 2% | 1% |
| ISG-DSG, Difference (95% CI)†,‡ | 0.7% (-1.3%, 2.6%) | |
| HIV-1 RNA <50 copies/mL | 91% | 95% |
| No Virologic Data Within the Time Window | 8% | 4% |
| Discontinued study due to AE or Death§ | 3% | <1% |
| Discontinued study for Other Reasons¶ | 4% | 4% |
| On study but missing data in window | 0 | 0 |
| Proportion (%) of Participants With HIV-1 RNA <50 copies/mL by Baseline and Demographic Category | ||
| Age (years) | ||
| < 50 | 90% (N = 320) | 95% (N = 157) |
| ≥ 50 | 94% (N = 127) | 94% (N = 66) |
| Gender | ||
| Male | 91% (N = 372) | 94% (N = 194) |
| Female | 91% (N = 75) | 100% (N = 29) |
| Race | ||
| White | 90% (N = 344) | 95% (N = 168) |
| Non-White | 93% (N = 103) | 93% (N = 55) |
| Ethnicity | ||
| Hispanic or Latino | 88% (N = 99) | 91% (N = 45) |
| Not Hispanic or Latino | 91% (N = 341) | 95% (N = 175) |
| CD4+ T-cell Count (cells/mm³) | ||
| <200 cells/mm³ | 85% (N = 13) | 75% (N = 4) |
| ≥200 cells/mm³ | 91% (N = 426) | 95% (N = 216) |
| Baseline Regimen# | ||
| PI plus either ritonavir or cobicistat | 90% (N=316) | 94% (N=156) |
| elvitegravir plus cobicistat or NNRTI | 93% (N = 131) | 96% (N=67) |
| * Includes participants who discontinued study drug or study before Week 48 for ISG or before Week 24 for DSG for lack or loss of efficacy and participants with HIV-1 RNA ≥50 copies/mL in the Week 48 window for ISG and in the Week 24 window for DSG. † The 95% CI for the treatment difference was calculated using stratum-adjusted Mantel- Haenszel method. ‡ Assessed using a non-inferiority margin of 4%. § Includes participants who discontinued because of adverse event (AE) or death if this resulted in no virologic data on treatment during the specified window. ¶ Other reasons include: lost to follow-up, non-compliance with study drug, physician decision, protocol deviation, withdrawal by participant. # Baseline Regimen = PI plus either ritonavir or cobicistat (specifically atazanavir, darunavir, or lopinavir), or elvitegravir plus cobicistat, or NNRTI (specifically efavirenz, nevirapine, or rilpivirine), each administered with two NRTIs. |
||
The efficacy of DELSTRIGO (DOR/3TC/TDF) was evaluated in cohort 2 of an open-label, single-arm 2-cohort trial in pediatric participants 12 to less than 18 years of age living with HIV (IMPAACT 2014 (Protocol 027), NCT03332095). In cohort 1, virologicallysuppressed participants (n=9) received a single 100 mg dose of PIFELTRO followed by intensive PK sampling. In cohort 2, virologically-suppressed participants (n=43) were switched to DELSTRIGO and treatment-naïve participants (n=2) were started on DELSTRIGO.
In cohort 2, at baseline the median age of participants was 15 years (range: 12 to 17), the median weight was 52 kg (range: 45 to 80), 58% were female, 78% were Asian and 22% were Black, and the median CD4+ T-cell count was 713 cells per mm³ (range 84 to 1397). After switching to DELSTRIGO, 95% (41/43) of virologically-suppressed participants remained suppressed (HIV-1 RNA <50 copies/mL) at Week 24. One of the two treatment-naïve participants achieved HIV-1 RNA <50 copies/mL at Week 24. The other treatment-naïve participant met the protocol-defined virologic failure criteria (defined as 2 consecutive plasma HIV-1 RNA test results ≥200 copies/mL at or after Week 24) and was evaluated for the development of resistance; no emergence of genotypic or phenotypic resistance to doravirine, lamivudine, or tenofovir was detected.
PIFELTRO®
(pih-FEL-tro)
(doravirine) tablets
What is PIFELTRO?
PIFELTRO is a prescription medicine that is used together with other HIV-1 medicines to treat Human Immunodeficiency Virus-1 (HIV-1) infection in adults and children who weigh at least 77 pounds (35 kg):
HIV-1 is the virus that causes Acquired Immune Deficiency Syndrome (AIDS). It is not known if PIFELTRO is safe and effective in children who weigh less than 77 pounds (35 kg).
Who should not take PIFELTRO?
Do not take PIFELTRO if you take any of the following medicines:
Ask your healthcare provider or pharmacist if you are not sure if your medicine is one that is listed above. If you have taken any of the medicines in the past 4 weeks, talk to your healthcare provider or pharmacist before starting treatment with PIFELTRO.
What should I tell my healthcare provider before treatment with PIFELTRO?
Before treatment with PIFELTRO, tell your healthcare provider about all of your medical conditions, including if you:
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.
How do I take PIFELTRO?
What are the possible side effects of PIFELTRO?
PIFELTRO can cause serious side effects, including:
The most common side effects of PIFELTRO include:
These are not all of the possible side effects of PIFELTRO.
Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
How should I store PIFELTRO?
Keep PIFELTRO and all medicines out of the reach of children.
General information about the safe and effective use of PIFELTRO.
Medicines are sometimes prescribed for purposes other than those listed in the Patient Information leaflet. Do not use PIFELTRO for a condition for which it was not prescribed. Do not give PIFELTRO to other people, even if they have the same symptoms that you have. It may harm them. You can ask your pharmacist or healthcare provider for information about PIFELTRO that is written for healthcare professionals.
What are the ingredients in PIFELTRO?
Active ingredient: doravirine.
Inactive ingredients: colloidal silicon dioxide, croscarmellose sodium, hypromellose acetate succinate, lactose monohydrate, magnesium stearate, and microcrystalline cellulose. The tablet film coating contains hypromellose, lactose monohydrate, titanium dioxide and triacetin. The coated tablets are polished with carnauba wax.
This Patient Information has been approved by the U.S. Food and Drug Administration.
